ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
May 07, 2021 01:00 JST
Source:
Avance Clinical
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand
ADELAIDE, AUS, May 07, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).
This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).
In Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology Act 2000. The OGTR administers the Gene Technology Act 2000, and has specific responsibility to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating dealings with GMOs.
The global market for genetic modification therapies is expected to grow from $2.3 billion in 2018 to reach $17.4 billion by 2023, growing at a compound annual growth rate of 49.9% (BCC Research, 2018). The utilization of gene modification technologies used in COVID-19 vaccine products is likely to translate in further growth in this field of therapeutics.
Avance Clinical CEO Yvonne Lungershausen said OGTR accreditation is important for our international clients. "Our clients need to know that their CRO has all the necessary credentials and is capable of delivering the highest of clinical research standards in this exciting and rapidly evolving sector," she said.
Avance Clinical currently has a number of GMO studies underway and is expanding its services further to accommodate increasing global demand.
Take the Quiz: Test your Knowledge about Australian Clinical Trials here.
https://www.surveymonkey.com/r/Australian-Clinical-Trials
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit
http://www.avancecro.com
for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV
May 22, 2025 13:35 JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21, 2025 15:00 JST
New RAV4 Makes World Premiere in Japan
May 21, 2025 14:09 JST
Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer
May 21, 2025 14:00 JST
MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines
May 20, 2025 13:51 JST
MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT
May 19, 2025 16:14 JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16, 2025 17:21 JST
Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America
May 16, 2025 16:35 JST
Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States
May 16, 2025 15:43 JST
MHI Thermal Systems Receives JSRAE Technology Award
May 15, 2025 20:08 JST
Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology
May 15, 2025 13:37 JST
Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets
May 15, 2025 11:00 JST
MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station
May 14, 2025 16:50 JST
Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects
May 14, 2025 11:00 JST
More Latest Release >>
Related Release
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
July 23 2024 16:00 JST
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 04 2024 22:00 JST
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
More Press release >>